Skip to content
Screener

Madrigal Pharmaceuticals, Inc. MDGL Total Operating Expenses

Total Operating Expenses at other companies

Altimmune logo
AltimmuneALT
$24.24M+11.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$164.13M+196%
Wave Life Sciences logo
Wave Life SciencesWVE
$76.07M+23.8%
Arrowhead Research logo
Arrowhead ResearchARWR
$215M+33.1%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$218.78M+64.8%
Maze Therapeutics logo
Maze TherapeuticsMAZE
$46.55M+31.5%

Other financials

Income statement

See full
Revenue$364.3M+71.2%
Gross profit$43.5M
Operating income-$56.3M-19.3%
Net income-$57.9M-37.0%
EPS (diluted)-$1.99-4.7%

Balance sheet

See full
Cash & equivalents$292.9M+53.2%
Total debt$377.9M+179%
Total equity$523.7M-24.7%
Total assets$1.2B+22.6%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$4.3M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.88B+57.6%
Enterprise value$11.96B+59.9%
P/S9.3×-5.4×

Profitability

See full
Gross margin96.5%
Operating margin-25.1%-9.2pp
Net margin-25.3%-8.8pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-53.3%+47.0pp
Debt / equity0.7×+0.5×
Current ratio3.2×-1.9×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050845
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of sales40,0079,06566,85413,578
Research and development91,17854,081199,87098,253
Selling, general and administrative289,375196,858557,896364,734
Total operating expenses420,560260,004824,620476,565
Loss from operations(56,308)(47,202)(149,031)(126,513)
Interest income7,1048,22715,34717,597
Interest expense(7,940)(3,264)(15,759)(6,561)
Other expense, net(795)(42)(2,887)(42)

Item 1. Financial Statements (Unaudited):

FAQ

What is Madrigal Pharmaceuticals, Inc.'s total operating expenses?
Madrigal Pharmaceuticals, Inc. (MDGL) reported total operating expenses of $420.56M in Q2 2026.
How has Madrigal Pharmaceuticals, Inc.'s total operating expenses changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s total operating expenses increased by 61.8% year-over-year, from $260M to $420.56M.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s total operating expenses?
Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s total operating expenses has grown at a 50.9% compound annual growth rate (CAGR), from $242.48M to $1.26B.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Madrigal Pharmaceuticals, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude